TABLE OF CONTENTS
1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF EUROPE PHARMACEUTICAL SOLVENT MARKET 46
1.4 LIMITATIONS 47
1.5 MARKETS COVERED 47
2 MARKET SEGMENTATION 50
2.1 MARKETS COVERED 50
2.2 GEOGRAPHICAL SCOPE 51
2.3 YEARS CONSIDERED FOR THE STUDY 52
2.4 CURRENCY AND PRICING 52
2.5 DBMR TRIPOD DATA VALIDATION MODEL 53
2.6 PRODUCT LIFE LINE CURVE 56
2.7 MULTIVARIATE MODELLING 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 VENDOR SHARE ANALYSIS 61
2.11 MARKET APPLICATION COVERAGE GRID 62
2.12 DBMR MARKET CHALLENGE MATRIX 63
2.13 SECONDARY SOURCES 64
2.14 ASSUMPTIONS 65
3 EXECUTIVE SUMMARY 66
4 PREMIUM INSIGHTS 69
4.1 RAW MATERIAL OUTLOOK 70
4.2 ADOPTION SCENARIO AMONG BUYERS 71
4.3 VALUE CHAIN ANALYSIS 72
5 MARKET OVERVIEW 73
5.1 DRIVERS 75
5.1.1 GROWTH IN PHARMACEUTICAL, AND HEALTHCARE SECTOR ACROSS THE GLOBE 75
5.1.2 RISE IN PRODUCTION OF INNOVATIVE GENERIC DRUGS, PARTICULARLY IN EMERGING ECONOMIES 76
5.1.3 INCREASE IN DEMAND FOR ALCOHOL SOLVENTS FOR MANUFACTURING OF VARIOUS DRUGS 77
5.2 RESTRAINTS 79
5.2.1 HIGH PRODUCTION COSTS, AND COMPLEX MANUFACTURING PROCESS 79
5.2.2 STRINGENT REGULATIONS REGARDING THE USE OF CERTAIN CONVENTIONAL SOLVENTS 80
5.3 OPPORTUNITIES 81
5.3.1 GROWTH IN RESEARCH AND DEVELOPMENT ACTIVITIES 81
5.3.2 DEVELOPMENT OF NEW DRUG MANUFACTURING METHODS AND TECHNOLOGIES 82
5.3.3 RISE IN ADOPTION OF GREEN MATERIALS AND CHEMICALS FOR DRUG MANUFACTURING 84
5.4 CHALLENGES 85
5.4.1 RISE IN CONCERNS REGARDING THE TOXICITY OF SOLVENTS 85
5.4.2 OCCURRENCES OF FATALITIES IN THE PHARMACEUTICAL SOLVENT MANUFACTURING COMPANIES 86
6 ANALYSIS ON IMPACT OF COVID-19 ON THE MARKET 87
6.1 AFTERMATH OF COVID-19 AND THE GOVERNMENT INITIATIVE TO BOOST THE MARKET 87
6.2 STRATEGIC DECISIONS OF MANUFACTURERS AFTER COVID-19 TO GET COMPETITIVE MARKET SHARE 87
6.3 IMPACT ON PRICE 88
6.4 IMPACT ON DEMAND 88
6.5 IMPACT ON SUPPLY CHAIN 88
6.6 CONCLUSION 89
7 EUROPE PHARMACEUTICAL SOLVENT MARKET, BY PRODUCT 90
7.1 OVERVIEW 91
7.2 ALCOHOL 93
7.2.1 METHANOL 95
7.2.2 ETHANOL 95
7.2.3 1-BUTANOL 95
7.2.4 2-BUTANOL 95
7.2.5 2-METHOXYETHANOL 95
7.2.6 3-METHYL-1-PROPANOL 95
7.2.7 2-METHYL-1-PROPANOL 95
7.2.8 1-PENTANOL 95
7.2.9 1-PROPANOL 95
7.2.10 2-PROPANOL (ISOPROPYL ALCOHOL) 95
7.2.11 OTHERS 96
7.3 AROMATIC HYDROCARBONS 96
7.3.1 TOLUENE 98
7.3.2 XYLENE 98
7.3.3 ETHYLBENZENE 98
7.3.4 OTHERS 98

7.4 KETONES 98
7.4.1 ACETONE 100
7.4.2 CYCLOHEXANONE 100
7.4.3 METHYL ETHER KETONE 100
7.4.4 METHYL ETHYL KETONE 100
7.4.5 METHYL ISOBUTYL KETONE 100
7.4.6 OTHERS 100
7.5 ETHERS 101
7.5.1 DIETHYL ETHER 102
7.5.2 METHOXYETHANE 102
7.5.3 TETRAHYDROFURAN 102
7.5.4 METHYL TERT-BUTYL ETHER 103
7.5.5 DI-N-PROPYL ETHER 103
7.5.6 OTHERS 103
7.6 AMINE 103
7.6.1 MONOETHANOLAMINE (MEA) 105
7.6.2 DIETHANOLAMINE (DEA) 105
7.6.3 METHYLDIETHANOLAMINE (MDEA) 105
7.6.4 OTHERS 105
7.7 ESTERS 105
7.7.1 ACETYL ACETATE 106
7.7.2 ETHYL ACETATE 107
7.7.3 BUTYL ACETATE 107
7.7.4 OTHERS 107
7.8 CHLORINATED SOLVENTS 107
7.8.1 TRICHLOROETHYLENE (TCE) 109
7.8.2 PERCHLOROETHYLENE (PCE) 109
7.8.3 1,1,1-TRICHLOROETHANE (TCA) 109
7.8.4 OTHERS 109
7.9 OTHERS 110
8 EUROPE PHARMACEUTICAL SOLVENT MARKET, BY APPLICATION 111
8.1 OVERVIEW 112
8.2 PHARMACEUTICAL 114
8.3 RESEARCH LABORATORIES 115
8.4 CHEMICAL 116
8.5 OTHERS 117

9 EUROPE PHARMACEUTICAL SOLVENT MARKET 118
9.1 EUROPE 119
9.1.1 SWITZERLAND 131
9.1.2 ITALY 138
9.1.3 GERMANY 145
9.1.4 FRANCE 152
9.1.5 U.K. 159
9.1.6 SPAIN 166
9.1.7 BELGIUM 172
9.1.8 NETHERLANDS 179
9.1.9 RUSSIA 186
9.1.10 TURKEY 193
9.1.11 LUXEMBURG 200
9.1.12 REST OF EUROPE 207
10 EUROPE PHARMACEUTICAL SOLVENT MARKET: COMPANY LANDSCAPE 208
10.1 COMPANY SHARE ANALYSIS: EUROPE 208
10.2 MERGERS & ACQUISITIONS 209
10.3 EXPANSION 209
10.4 NEW PRODUCT DEVELOPMENT 209
10.5 PARTNERSHIP 210
10.6 AGREEMENTS 210
10.7 AWARD AND CERTIFICATION 210
11 SWOT ANALYSIS 211
12 COMPANY PROFILE 212
12.1 ROYAL DUTCH SHELL PLC 212
12.1.1 COMPANY SNAPSHOT 212
12.1.2 REVENUS ANALYSIS 212
12.1.3 COMPANY SHARE ANALYSIS 213
12.1.4 PRODUCT PORTFOLIO 213
12.1.5 RECENT DEVELOPMENT 214
12.2 BASF SE 215
12.2.1 COMPANY SNAPSHOT 215
12.2.2 REVENUS ANALYSIS 215
12.2.3 COMPANY SHARE ANALYSIS 216
12.2.4 PRODUCT PORTFOLIO 216
12.2.5 RECENT DEVELOPMENT 217

12.3 MERCK KGAA 218
12.3.1 COMPANY SNAPSHOT 218
12.3.2 REVENUE ANALYSIS 218
12.3.3 COMPANY SHARE ANALYSIS 219
12.3.4 PRODUCT PORTFOLIO 219
12.3.5 RECENT DEVELOPMENT 219
12.4 EXXON MOBIL CORPORATION 220
12.4.1 COMPANY SNAPSHOT 220
12.4.2 REVENUE ANALYSIS 220
12.4.3 COMPANY SHARE ANALYSIS 221
12.4.4 PRODUCT PORTFOLIO 221
12.4.5 RECENT DEVELOPMENT 221
12.5 BRENNTAG SE 222
12.5.1 COMPANY SNAPSHOT 222
12.5.2 REVENUE ANALYSIS 222
12.5.3 COMPANY SHARE ANALYSIS 223
12.5.4 PRODUCT PORTFOLIO 223
12.5.5 RECENT DEVELOPMENT 225
12.6 DUPONT 225
12.6.1 COMPANY SNAPSHOT 225
12.6.2 REVENUS ANALYSIS 226
12.6.3 PRODUCT PORTFOLIO 226
12.6.4 RECENT DEVELOPMENTS 227
12.7 MITSUI CHEMICALS 228
12.7.1 COMPANY SNAPSHOT 228
12.7.2 REVENUE ANALYSIS 228
12.7.3 PRODUCT PORTFOLIO 229
12.7.4 RECENT DEVELOPMENT 229
12.8 DOW 230
12.8.1 COMPANY SNAPSHOT 230
12.8.2 REVENUS ANALYSIS 230
12.8.3 PRODUCT PORTFOLIO 231
12.8.4 RECENT DEVELOPMENT 231
12.9 LYONDELLBASELL INDUSTRIES HOLDINGS B.V. 233
12.9.1 COMPANY SNAPSHOT 233
12.9.2 REVENUS ANALYSIS 233
12.9.3 PRODUCT PORTFOLIO 234
12.9.4 RECENT DEVELOPMENT 237

12.10 CLARIANT AG 239
12.10.1 COMPANY SNAPSHOT 239
12.10.2 REVENUE ANALYSIS 240
12.10.3 PRODUCT PORTFOLIO 240
12.10.4 RECENT DEVELOPMENT 241
12.11 AVANTOR, INC. 242
12.11.1 COMPANY SNAPSHOT 242
12.11.2 REVENUE ANALYSIS 242
12.11.3 PRODUCT PORTFOLIO 243
12.11.4 RECENT DEVELOPMENT 243
12.12 EASTMAN CHEMICAL COMPANY 244
12.12.1 COMPANY SNAPSHOT 244
12.12.2 REVENUS ANALYSIS 244
12.12.3 PRODUCT PORTFOLIO 245
12.12.4 RECENT DEVELOPMENT 245
12.13 OLIN CORPORATION 246
12.13.1 COMPANY SNAPSHOT 246
12.13.2 REVENUE ANALYSIS 246
12.13.3 PRODUCT PORTFOLIO 247
12.13.4 RECENT DEVELOPMENT 247
12.14 SK GEO CENTRIC CO., LTD. (A SUBSIDIARY OF SK EUROPE CHEMICAL) 248
12.14.1 COMPANY SNAPSHOT 248
12.14.2 PRODUCT PORTFOLIO 248
13 QUESTIONNAIRE 250
14 RELATED REPORTS 252

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.